Staying up-to-date on the latest drug and healthcare policy updates can be a full-time job. To help you keep track of it all, Cardinal Health Specialty Solutions invited legislative and policy expert Dr. Joe Bailes to our recent Channel Management Forum. Trained as a medical oncologist, Dr. Bailes has extensive experience in public policy and advocacy. He is also former President and CEO of the American Society for Clinical Oncology (ASCO) and currently serves on the board of the ASCO foundation.
Speaking on the day that President Trump had originally been scheduled to release his healthcare and drug pricing plan, (which was announced two weeks later, on May 11) Dr. Bailes offered an informed prognosis on its potential impact.
Dr. Bailes identified the movement of Part B drugs to Part D as a potential attempt by the administration to control drug prices, a move that carries implications for newly-approved products. In fact, the now-released plan does call for a report to the President on whether lower prices on some Medicare Part B drugs could be negotiated for by Part D plans.
On the topic of 340B pricing, Dr. Bailes detailed bills in front of Congress to drive auditing, accountability and transparency related to 340B revenue. While these proposals are largely sympathetic to pharma, they may face challenges from members of Congress, many of whom have large hospitals in their districts – the largest employers in the area for a third of these legislators.
While what may happen next in Washington is hard to predict, you can gain insights and perspectives from a seasoned expert by listening to Dr. Bailes’ full Channel Management Forum presentation.